Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

NCT04139772 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistent Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Abiraterone Acetate or Enzalutamide

Sponsor

National Cancer Institute, Naples